BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in
BioSpace
In addition to delivering two approved medicines to Biogen's portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma's own kidney disease asset, currently in
BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in